← Leaderboards
Todd M Zimmerman
University Of Chicago
$653,205
Attributed
$653,205
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $131.1K · FY2005–06$200K$150K$100K$50K$0
'05
'06
Funding mix
By agency
NIH$653,205 · 1
By mechanism
K23$653,205 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Mark J Ratain$26,736,475
- Richard L Schilsky$24,946,699
- Marcus R Clark$42,942,393
- M Eileen Dolan$15,055,139
- Michelle M Le Beau$39,023,275
Others in their field
Top investigators on “Clinical Trial Phase I”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Lawrence Corey · Fred Hutchinson Cancer Center$674,722,986
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$549,289,302
- Barton F Haynes · Duke University$532,133,792
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$407,280,377
Research focus
Clinical Trial Phase IDrug Screening /EvaluationBlood /Lymphatic NeoplasmHuman SubjectHuman Therapy EvaluationImmunohematologyImmunopharmacologyImmunotherapyMultiple MyelomaPatient Oriented ResearchPharmacokineticsRenal FailureClinical ResearchDosage
Grant awards (5)
Novel Therapies for Myeloma and Related Malignancies$131,058
K23 · FY2006 · CA · contact PI
Novel Therapies for Myeloma and Related Malignancies$131,058
K23 · FY2005 · CA
Novel Therapies for Myeloma and Related Malignancies$130,363
K23 · FY2004 · CA
Novel Therapies for Myeloma and Related Malignancies$130,363
K23 · FY2003 · CA
Novel Therapies for Myeloma and Related Malignancies$130,363
K23 · FY2002 · CA